Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 26, 2025
FY End Sale – Get 20% Off on Global Market Reports By The Business Research Company Before March 31st!
EIN Presswire
·
March 26, 2025
Exclusive Market Insights to Drive Growth – Save 20% for a Limited Time LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /EINPresswire.com/ -- Unlock Exclusive Market Insights to Drive Growth …
Sister2Sister and Unite Genomics Partner to Enhance Breast Cancer Care for Minority and Underserved Communities
EIN Presswire
·
March 26, 2025
The partners will leverage AI to help breast cancer patients navigate care, address treatment gaps, and improve outcomes SOMERSET, NJ, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Sister2Sister, a leading breast cancer survivorship organization, …
Mitolyn Reviews (DOCTOR INVESTIGATES) Can It Really Boost Energy, Burn Fat & Support Mitochondria Naturally?
GlobeNewswire
·
March 26, 2025
Seattle, March 26, 2025 (GLOBE NEWSWIRE) -- Mitolyn With the massive flood of weight loss and energy-boosting supplements on the market, it’s easy to be skeptical of Mitolyn. Is it truly a science-backed solution for metabolism and fat loss, or just …
New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health
EIN Presswire
·
March 26, 2025
Empowers Patients and Caregivers ST PETERSBURG, FL, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health Empowers Patients and Caregivers Today marks the launch …
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
GlobeNewswire
·
March 26, 2025
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
GlobeNewswire
·
March 26, 2025
EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings from Spherix’s fifth annual Patient Chart Dynamix™ : IgA …
Avotres Inc. Founder and CSO, Dr. Hong Jiang Presented at the 7th Treg-Directed Therapies Summit
EIN Presswire
·
March 26, 2025
BOSTON, MA, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Avotres proudly announces the successful presentation, titled as “Analyzing the Q/E CD8+ Treg Pathway to Unlock Effective Clinical Applications: Q/E CD8+Treg Pathway Directed Therapy for …
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 26, 2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed …
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement
GlobeNewswire
·
March 26, 2025
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement Revenu total de 83,4 millions d’euros et position de trésorerie1 de 64,2 millions d’euros au 31 décembre 2024, assurant une visibilité …
Global Guillain Barre Syndrome Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
EIN Presswire
·
March 26, 2025
The Business Research Company's Guillain-Barre Syndrome Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: …
In-Depth Analysis Of The Global Growth Hormone Deficiency Market: Key Drivers, Trends, Growth And Forecast 2025-2034
EIN Presswire
·
March 26, 2025
The Business Research Company's Growth Hormone Deficiency Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: …
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
GlobeNewswire
·
March 26, 2025
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration …
Valneva renouvelle son contrat de placement (Sales Agreement) dans le cadre de son programme « At-the-Market (ATM) » existant
GlobeNewswire
·
March 26, 2025
Saint-Herblain (France), 26 mars 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce aujourd’hui qu’elle a déposé auprès de la U.S. Securities and Exchange Commission (« …
GUERBET : 2024 full-year results.
GlobeNewswire
·
March 26, 2025
2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER)1 and on a like-for-like basis2 Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA …
GUERBET : Résultats annuels 2024.
GlobeNewswire
·
March 26, 2025
Résultats annuels 2024 Activité très dynamique Chiffre d’affaires annuel : 841,1 M€, affichant une progression de 9,0% à taux de change constant (TCC)1 et périmètre comparable2 Une dynamique soutenue dans la zone Amériques (+20,5% à TCC et périmètre …
PrimeBiome Reviews - Is it Worth Buying? Prime Biome Gummies Ingredients, Side Effects, and Investigative Report
GlobeNewswire
·
March 26, 2025
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- PrimeBioMe is a natural dietary supplement designed to support gut health, improve digestion, and enhance skin appearance. It is made with a blend of plant-based ingredients, it helps balance the gut …
iTeos präsentiert präklinische Daten zu EOS-215 – dem potenziellen Best-in-Class-Antikörper gegen TREM2 und neuartigen PTPN1/2-Inhibitor – auf der Jahrestagung 2025 der American Association for Cancer Research
GlobeNewswire
·
March 26, 2025
WATERTOWN, Mass. und GOSSELIES, Belgien, March 26, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen im Bereich der klinischen Forschung, das Pionierarbeit bei der Erforschung und Entwicklung einer neuen …
iTeos présentera les données précliniques d’EOS-215, un anticorps anti-TREM2 supposé meilleur de sa catégorie, et d’un nouvel inhibiteur de PTPN1/2 lors de l’édition 2025 du congrès annuel de l’American Association for Cancer Research
GlobeNewswire
·
March 26, 2025
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 26 mars 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le développement d’une nouvelle génération de …
OmegaX Health ($OmegaX) Expands to Binance Smart Chain – The Future of AI Healthcare on Blockchain
GlobeNewswire
·
March 26, 2025
ELLWANGEN, Germany, March 26, 2025 (GLOBE NEWSWIRE) -- OmegaX Health ($OmegaX), a groundbreaking AI-powered healthcare ecosystem, is set to redefine the future of medicine by combining artificial intelligence and blockchain technology. Following a highly …
US Hematologists Show Cautious Optimism as Data Reveal Early Adoption Trends for Hympavzi (Pfizer) and Alhemo (Novo Nordisk) in Hemophilia A and B, According to Spherix Global Insights
GlobeNewswire
·
March 26, 2025
EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies, Hemlibra, and Altuvio to create new options. The latest …